Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$3.4 million.

  • CG Oncology's Change in Accured Expenses fell 180.39% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 112.55%. This contributed to the annual value of $5.5 million for FY2024, which is 32.17% up from last year.
  • As of Q3 2025, CG Oncology's Change in Accured Expenses stood at -$3.4 million, which was down 145.25% from $7.5 million recorded in Q2 2025.
  • CG Oncology's Change in Accured Expenses' 5-year high stood at $7.5 million during Q2 2025, with a 5-year trough of -$4.1 million in Q1 2024.
  • In the last 3 years, CG Oncology's Change in Accured Expenses had a median value of $1.5 million in 2023 and averaged $1.3 million.
  • In the last 5 years, CG Oncology's Change in Accured Expenses plummeted by 2,712.03% in 2024 and then soared by 263.53% in 2025.
  • CG Oncology's Change in Accured Expenses (Quarterly) stood at $1.8 million in 2023, then soared by 89.98% to $3.3 million in 2024, then plummeted by 180.39% to -$3.4 million in 2025.
  • Its Change in Accured Expenses stands at -$3.4 million for Q3 2025, versus $7.5 million for Q2 2025 and $836,000 for Q1 2025.